We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
In the latest close session, Adma Biologics (ADMA - Free Report) was down 2.42% at $8.46. This change lagged the S&P 500's daily gain of 0.7%. Meanwhile, the Dow experienced a rise of 0.53%, and the technology-dominated Nasdaq saw an increase of 1%.
Shares of the infectious disease drug developer have depreciated by 3.13% over the course of the past month, underperforming the Medical sector's gain of 1.76%, and the S&P 500's loss of 0.49%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. The company's earnings report is expected on August 5, 2026. The company is predicted to post an EPS of $0.16, indicating a 6.67% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $125.77 million, reflecting a 3.11% rise from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.8 per share and a revenue of $534.15 million, indicating changes of +33.33% and +4.7%, respectively, from the former year.
Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 2.03% lower within the past month. Right now, Adma Biologics possesses a Zacks Rank of #5 (Strong Sell).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 10.79. This expresses a discount compared to the average Forward P/E of 20.65 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 84, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
In the latest close session, Adma Biologics (ADMA - Free Report) was down 2.42% at $8.46. This change lagged the S&P 500's daily gain of 0.7%. Meanwhile, the Dow experienced a rise of 0.53%, and the technology-dominated Nasdaq saw an increase of 1%.
Shares of the infectious disease drug developer have depreciated by 3.13% over the course of the past month, underperforming the Medical sector's gain of 1.76%, and the S&P 500's loss of 0.49%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. The company's earnings report is expected on August 5, 2026. The company is predicted to post an EPS of $0.16, indicating a 6.67% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $125.77 million, reflecting a 3.11% rise from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.8 per share and a revenue of $534.15 million, indicating changes of +33.33% and +4.7%, respectively, from the former year.
Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 2.03% lower within the past month. Right now, Adma Biologics possesses a Zacks Rank of #5 (Strong Sell).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 10.79. This expresses a discount compared to the average Forward P/E of 20.65 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 84, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.